Inventiva S.A (IVA) - Total Liabilities
Based on the latest financial reports, Inventiva S.A (IVA) has total liabilities worth €278.03 Million EUR (≈ $325.05 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Inventiva S.A - Total Liabilities Trend (2013–2025)
This chart illustrates how Inventiva S.A's total liabilities have evolved over time, based on quarterly financial data. See Inventiva S.A (IVA) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Inventiva S.A Competitors by Total Liabilities
The table below lists competitors of Inventiva S.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shandong Mining Machinery Group Co Ltd
SHE:002526
|
China | CN¥2.05 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥130.20 Million |
|
Dalian Sunasia Tourism Holding Co Ltd
SHG:600593
|
China | CN¥1.63 Billion |
|
GCI Liberty, Inc.
NASDAQ:GLIBK
|
USA | $1.52 Billion |
|
AB SKF (publ)
ST:SKF-A
|
Sweden | Skr52.19 Billion |
|
Dilip Buildcon Limited
NSE:DBL
|
India | Rs144.99 Billion |
|
Kvutzat Acro Ltd.
TA:ACRO
|
Israel | ILA4.96 Billion |
|
Resurs Holding AB
ST:RESURS
|
Sweden | Skr42.62 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Inventiva S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Inventiva S.A stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -9.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Inventiva S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Inventiva S.A (2013–2025)
The table below shows the annual total liabilities of Inventiva S.A from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €278.03 Million ≈ $325.05 Million |
+23.23% |
| 2024-12-31 | €225.61 Million ≈ $263.77 Million |
+122.08% |
| 2023-12-31 | €101.59 Million ≈ $118.77 Million |
+44.04% |
| 2022-12-31 | €70.53 Million ≈ $82.45 Million |
+112.96% |
| 2021-12-31 | €33.12 Million ≈ $38.72 Million |
+19.53% |
| 2020-12-31 | €27.71 Million ≈ $32.39 Million |
+77.98% |
| 2019-12-31 | €15.57 Million ≈ $18.20 Million |
-14.54% |
| 2018-12-31 | €18.22 Million ≈ $21.30 Million |
+75.86% |
| 2017-12-31 | €10.36 Million ≈ $12.11 Million |
-21.15% |
| 2016-12-31 | €13.14 Million ≈ $15.36 Million |
-26.22% |
| 2015-12-31 | €17.81 Million ≈ $20.82 Million |
-17.67% |
| 2014-12-31 | €21.63 Million ≈ $25.28 Million |
-23.05% |
| 2013-12-31 | €28.11 Million ≈ $32.86 Million |
-- |
About Inventiva S.A
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat … Read more